CIZ1
Chr 9CDKN1A interacting zinc finger protein 1
May regulate the subcellular localization of CIP/WAF1
569
ClinVar variants
19
Pathogenic / LP
0.06
pLI score
0
Active trials
Clinical Summary— CIZ1
⚡
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.25) despite low pLI — interpret in context.
📋
ClinVar Variants
19 Pathogenic / Likely Pathogenic· 238 VUS of 569 total submissions
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Moderate LoF intolerance
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.40LOEUF
pLI 0.063
Z-score 4.98
OE 0.25 (0.16–0.40)
More LoF-intolerant than ~75% of genes
Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.99Z-score
OE missense 0.75 (0.69–0.82)
371 obs / 495.6 exp
Mild missense constraint
Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.25 (0.16–0.40)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.75 (0.69–0.82)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.93
0≤1.21.6
LoF obs/exp: 13 / 51.7Missense obs/exp: 371 / 495.6Syn Z: 0.79
ClinVar Variant Classifications
569 submitted variants in ClinVar
Classification Summary
Pathogenic19
VUS238
Likely Benign153
Benign49
Conflicting12
19
Pathogenic
238
VUS
153
Likely Benign
49
Benign
12
Conflicting
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | 0 | 1 | 18 | 0 | 19 |
Likely Pathogenic | 0 | 0 | 0 | 0 | 0 |
VUS | 3 | 196 | 36 | 3 | 238 |
Likely Benign | 0 | 10 | 44 | 99 | 153 |
Benign | 0 | 4 | 35 | 10 | 49 |
Conflicting | — | 12 | |||
| Total | 3 | 211 | 133 | 112 | 471 |
LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly
View in ClinVar →Protein Context — Lollipop Plot
CIZ1 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
OMIM — Genotype-Phenotype Relationships
1 OMIM entry
CDKN1A-INTERACTING ZINC FINGER PROTEIN 1; CIZ1
MIM #611420 · *
External Resources
Links to major genomics databases and tools
Variant Interpretation
Population Databases
Gene Resources
Expert Curation
ClinGen
Expert-curated gene-disease validity
GenCC
Gene Curation Coalition — multi-curator classifications
Orphanet
Rare disease encyclopedia and gene-disease associations
SFARI Gene
Autism-gene association scoring (SFARI)
PanelApp
Gene panels for rare disease diagnostics (Genomics England)
LOVD
Leiden Open Variation Database — variant listings
GeneReviews
Expert-authored summaries of heritable conditions (NCBI)
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
CIZ1-F, an alternatively spliced variant of the DNA replication protein CIZ1 with distinct expression and localisation, is overrepresented in early stage common solid tumours.
Swarts DRA et al.·Cell Cycle
2018
CIZ1 is upregulated in hepatocellular carcinoma and promotes the growth and migration of the cancer cells.
Wu J et al.·Tumour Biol
2016
Dystonia: an update on phenomenology, classification, pathogenesis and treatment.
Balint B et al.·Curr Opin Neurol
2014Review
A Clinical and Integrated Genetic Study of Isolated and Combined Dystonia in Taiwan.
Wu MC et al.·J Mol Diagn
2022
Blepharospasm: A genetic screening study in 132 patients.
Hammer M et al.·Parkinsonism Relat Disord
2019Cohort
Primary and secondary dystonic syndromes: an update.
Charlesworth G et al.·Curr Opin Neurol
2013Review
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
AURKB-driven dissolution of CIZ1-RNA assemblies from the inactive X chromosome in mitosis.
Byrom L et al.·Nucleic Acids Res
2026🔓 Open Access
Epigenetic deprogramming by disruption of CIZ1-RNA nuclear assemblies in early-stage breast cancers.
Turvey GL et al.·J Cell Biol
2025🔓 Open Access
Implication of the Mediator kinase module in CIZ1 recruitment and gene silencing by Xist during the initiation of X inactivation.
Chen J et al.·Epigenet Rep
2025
CIZ1 in Xist seeded assemblies at the inactive X chromosome.
Sofi S et al.·Front Cell Dev Biol
2023🔓 Open Access
CIZ1 aggravates gastric cancer progression via mediating FBXL19-AS1 and miR-339-3p.
Wan H et al.·Heliyon
2023🔓 Open Access
Top 5 resultsSearch Europe PMC ↗
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
No active trials found for this gene.
Search ClinicalTrials.gov →External Resources
Links to major genomics databases and tools
Variant Interpretation
Population Databases
Gene Resources
Expert Curation
ClinGen
Expert-curated gene-disease validity
GenCC
Gene Curation Coalition — multi-curator classifications
Orphanet
Rare disease encyclopedia and gene-disease associations
SFARI Gene
Autism-gene association scoring (SFARI)
PanelApp
Gene panels for rare disease diagnostics (Genomics England)
LOVD
Leiden Open Variation Database — variant listings
GeneReviews
Expert-authored summaries of heritable conditions (NCBI)